Cite
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.
MLA
Hamilton, E., et al. “A Phase I Dose Escalation and Expansion Trial of the Next-Generation Oral SERD Camizestrant in Women with ER-Positive, HER2-Negative Advanced Breast Cancer: SERENA-1 Monotherapy Results.” Annals of Oncology, vol. 35, no. 8, Aug. 2024, pp. 707–17. EBSCOhost, https://doi.org/10.1016/j.annonc.2024.04.012.
APA
Hamilton, E., Oliveira, M., Turner, N., García-Corbacho, J., Hernando, C., Ciruelos, E. M., Kabos, P., Ruiz-Borrego, M., Armstrong, A., Patel, M. R., Vaklavas, C., Twelves, C., Boni, V., Incorvati, J., Brier, T., Gibbons, L., Klinowska, T., Lindemann, J. P. O., Morrow, C. J., & Sykes, A. (2024). A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results. Annals of Oncology, 35(8), 707–717. https://doi.org/10.1016/j.annonc.2024.04.012
Chicago
Hamilton, E., M. Oliveira, N. Turner, J. García-Corbacho, C. Hernando, E.M. Ciruelos, P. Kabos, et al. 2024. “A Phase I Dose Escalation and Expansion Trial of the Next-Generation Oral SERD Camizestrant in Women with ER-Positive, HER2-Negative Advanced Breast Cancer: SERENA-1 Monotherapy Results.” Annals of Oncology 35 (8): 707–17. doi:10.1016/j.annonc.2024.04.012.